ReviewAdvances in experimental medicine and biology2026
Proteomics in the Diagnosis of Viral and Pathogenic Infections.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While this book's theme is proteomics and virology, this chapter on the role of proteomics in clinical virology may seem unsatisfying to the reader. The reason is simple: proteomics has not made a major impact on the diagnosing of viral infections. However, it is still important to evaluate the present role of proteomics in clinical virology as it provides a vision of what is required if it is to ever have a major impact in diagnosing viral infections. This chapter will initially provide a background on current techniques for diagnosing viral infections. Although the names may not be familiar to the casual reader, the techniques will be as most individuals have been tested using one of these techniques during their lifetime. The chapter will later switch to describe proteomic methods for the direct detection of viruses in clinical samples. While outside the scope of this book, a proteomic method for bacterial identification is included because (i) it describes a proteomic technology that has been approved by the FDA for clinical use and (ii) since viruses and bacteria are both infectious agents it demonstrates the potential of proteomics for overall pathogen detection. To keep the topic in perspective, however, the advantages and disadvantages of using proteomics in clinical virology are compared to current existing methods particularly those that target the detection of genomic features within these pathogens.
Indexed as
Identifiers
42129071What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.